Skip to main content

Table 1 Dose-Reduction Criteria and Dose to be selected at Dose-Reduction

From: Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients

Item   Oxaliplatin 5-FU (bolus) 5-FU (infusion)
Neutrophil count < 500/mm 3 85 → 85 400 → 0 2,400 → 2,400
Platelet count < 50,000/mm 3 85 → 85 400 → 0 2,400 → 2,400
Non-hematological toxicity Grade 3 85 → 65 400 → 300 2,400 → 2,000
Skin symptoms Grade 3 85 → 85 400 → 300 2,400 → 2,000
Peripheral neuropathy Grade 2 85 → 65 400 → 400 2,400 → 2,400
Acute* 1 laryngopharyngeal dysesthesia
(feeling of difficulty in breathing)
  85 → 85
Infusion time is prolonged to
6 hours* 2
400 → 400 2,400 → 2,400
Peripheral neuropathy Grade 3 Discontinuation   
PS 3 Discontinuation   
  1. Abbreviation: PS, performance status
  2. *1 During the period from administration of oxaliplatin to 2 hours after completion of administration.
  3. *2 Administration of 5-FU should not be started until the completion of administration of oxaliplatin.